Please assess the completion status of the following clinical trial:

Trial Title: Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Experimental: Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb~* Active Comparator: Healthy Adult Volunteer~Exclusion Criteria:~All Participants:~* Less than 18 years of age~* History of hypersensitivity to ceftolozane/tazobactam, piperacillin/tazobactam, or any β-lactam antibiotic~* History of hypersensitivity to lidocaine or lidocaine derivatives~* Females who are pregnant or breastfeeding~* Concomitant receipt of any β-lactams antibiotic~* Concomitant receipt of probenecid~* Reduced kidney function defined as creatinine clearance of ≤ 50 mL/min~* Any other reason felt by the investigator to potentially affect the outcomes of the study~Experimental Group Only:~* No palpable pedal pulses present~* Participants likely to require multiple surgical interventions during the study period, which therefore could affect placement of the microdialysis catheter~Active Comparator Group Only:~* Positive urine drug screen (cocaine, tetrahydrocannabinol, opiates, benzodiazepines, and amphetamines)~* History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening.~* Use of tobacco- or nicotine-containing products in excess of the equivalence of 5 cigarettes per day.~* Use of prescription or nonprescription drugs, vitamins, or dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, with the exception of acetaminophen at doses of ≤ 1 g/day. Herbal supplements, hormonal methods of contraception (including oral and transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing intrauterine devices (IUDs), postcoital contraceptive methods), and hormone replacement therapy must be discontinued at least 14 days prior to the first dose of study medication. Depo-Provera® must be discontinued at least 6 months prior to the first dose of study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Diabetic Wound Infection (Type: EXPERIMENTAL): Participants with a documented history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours.
- Healthy Volunteer (Type: ACTIVE_COMPARATOR): Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid in the thigh by a microdialysis probe over 8 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).